200 related articles for article (PubMed ID: 31535081)
21. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract][Full Text] [Related]
22. The pro-proliferative effect of interferon-γ in breast cancer cell lines is dependent on stimulation of ASCT2-mediated glutamine cellular uptake.
Silva C; Andrade N; Rodrigues I; Ferreira AC; Soares ML; Martel F
Life Sci; 2021 Dec; 286():120054. PubMed ID: 34662550
[TBL] [Abstract][Full Text] [Related]
23. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
24. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence
Ding M; Bu X; Li Z; Xu H; Feng L; Hu J; Wei X; Gao J; Tao Y; Cai B; Liu Y; Qu X; Shen L
Int J Biol Sci; 2020; 16(16):3100-3115. PubMed ID: 33162818
[No Abstract] [Full Text] [Related]
25. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
[TBL] [Abstract][Full Text] [Related]
26. Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy.
Jiang H; Zhang N; Tang T; Feng F; Sun H; Qu W
Pharmacol Res; 2020 Aug; 158():104844. PubMed ID: 32438035
[TBL] [Abstract][Full Text] [Related]
27. Neddylation inhibition induces glutamine uptake and metabolism by targeting CRL3
Zhou Q; Lin W; Wang C; Sun F; Ju S; Chen Q; Wang Y; Chen Y; Li H; Wang L; Hu Z; Jin H; Wang X; Sun Y
Nat Commun; 2022 May; 13(1):3034. PubMed ID: 35641493
[TBL] [Abstract][Full Text] [Related]
28. Procyanidin B2 3,3″-di-O-gallate suppresses IFN-γ production in murine CD4
Endo K; Sawa T; Kitamura H; Umezawa K; Makabe H; Tanaka S
Int Immunopharmacol; 2023 Feb; 115():109617. PubMed ID: 36566519
[TBL] [Abstract][Full Text] [Related]
29. Establishment of monoclonal antibodies against cell surface domains of ASCT2/SLC1A5 and their inhibition of glutamine-dependent tumor cell growth.
Suzuki M; Toki H; Furuya A; Ando H
Biochem Biophys Res Commun; 2017 Jan; 482(4):651-657. PubMed ID: 27865832
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Willems L; Jacque N; Jacquel A; Neveux N; Maciel TT; Lambert M; Schmitt A; Poulain L; Green AS; Uzunov M; Kosmider O; Radford-Weiss I; Moura IC; Auberger P; Ifrah N; Bardet V; Chapuis N; Lacombe C; Mayeux P; Tamburini J; Bouscary D
Blood; 2013 Nov; 122(20):3521-32. PubMed ID: 24014241
[TBL] [Abstract][Full Text] [Related]
31. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.
Ren P; Yue M; Xiao D; Xiu R; Gan L; Liu H; Qing G
J Pathol; 2015 Jan; 235(1):90-100. PubMed ID: 25142020
[TBL] [Abstract][Full Text] [Related]
32. Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening.
Colas C; Grewer C; Otte NJ; Gameiro A; Albers T; Singh K; Shere H; Bonomi M; Holst J; Schlessinger A
PLoS Comput Biol; 2015 Oct; 11(10):e1004477. PubMed ID: 26444490
[TBL] [Abstract][Full Text] [Related]
33. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
[TBL] [Abstract][Full Text] [Related]
34. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
35. Topotecan induces hepatocellular injury via ASCT2 mediated oxidative stress.
Zhou G; Qin M; Zhang X; Yang J; Yu H
Gastroenterol Hepatol; 2021 Jan; 44(1):1-12. PubMed ID: 33039171
[TBL] [Abstract][Full Text] [Related]
36. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.
Bungard CI; McGivan JD
Biochem J; 2004 Aug; 382(Pt 1):27-32. PubMed ID: 15175006
[TBL] [Abstract][Full Text] [Related]
37. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.
Schulte ML; Khodadadi AB; Cuthbertson ML; Smith JA; Manning HC
Bioorg Med Chem Lett; 2016 Feb; 26(3):1044-1047. PubMed ID: 26750251
[TBL] [Abstract][Full Text] [Related]
38. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
39. Cellular distribution of the neutral amino acid transporter subtype ASCT2 in mouse brain.
Gliddon CM; Shao Z; LeMaistre JL; Anderson CM
J Neurochem; 2009 Jan; 108(2):372-83. PubMed ID: 19012749
[TBL] [Abstract][Full Text] [Related]
40. Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.
White MA; Lin C; Rajapakshe K; Dong J; Shi Y; Tsouko E; Mukhopadhyay R; Jasso D; Dawood W; Coarfa C; Frigo DE
Mol Cancer Res; 2017 Aug; 15(8):1017-1028. PubMed ID: 28507054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]